Going International with Gilead Sciences Inc.
Gilead Sciences Inc. (NASDAQ: GILD) is an international stock currently in the Cadence portfolio and was the first offshore listed position in the fund, initiated in mid-2014.
In summary, Gilead is a large US biotech stock specialising in antiviral drugs to treat patients suffering from HIV, hepatitis C, influenza and other medical conditions.
In 2014 it generated approximately US$25bn in revenue and currently has a market capitalisation of US$180 billion (this is larger than any company listed on the ASX). As the world’s leading anti-viral company, Gilead holds strong market positions in some very lucrative markets.
Click here to read the full article.
Frequently Asked Questions about this Article…
Gilead Sciences Inc. is a large US biotech company that specializes in antiviral drugs. They focus on treating patients with conditions such as HIV, hepatitis C, and influenza.
Cadence Capital Limited first invested in Gilead Sciences Inc. in mid-2014, marking it as the first offshore listed position in their fund.
Gilead Sciences Inc. is a major player in the biotech industry, known as the world's leading anti-viral company with strong market positions in lucrative markets.
In 2014, Gilead Sciences Inc. generated approximately US$25 billion in revenue.
Gilead Sciences Inc. has a market capitalization of US$180 billion, which is larger than any company listed on the ASX.
Investors might consider Gilead Sciences Inc. due to its strong market positions in antiviral drugs and its significant presence in lucrative markets, making it a potentially valuable addition to a diversified portfolio.
Gilead Sciences Inc. has a larger market capitalization than any company listed on the ASX, highlighting its substantial size and influence in the biotech sector.
Gilead Sciences Inc. focuses on developing antiviral drugs for medical conditions such as HIV, hepatitis C, and influenza, among others.
Call 1300 880 160
Start a chat
Schedule a call
